Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; hypromellose; iron oxide red; sodium stearylfumarate; microcrystalline cellulose - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; hypromellose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: iron oxide red; microcrystalline cellulose; sodium stearylfumarate; pregelatinised maize starch; hypromellose - treatment of hypertension. (data are currently not available to support the use of tritace in renovascular hypertension.) post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hypromellose; iron oxide yellow; pregelatinised maize starch; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of tritace in renovascular hypertension.) post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; hypromellose; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of tritace in renovascular hypertension.) post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

hoechst australia pty ltd - melatonin - no types entered yet

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glimepiride, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate; povidone; microcrystalline cellulose; indigo carmine - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glimepiride, quantity: 3 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; sodium starch glycollate; povidone; lactose monohydrate; magnesium stearate - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glimepiride, quantity: 2 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; magnesium stearate; microcrystalline cellulose; povidone; lactose monohydrate; indigo carmine; sodium starch glycollate - dimirel is indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.